These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11442014)

  • 21. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
    Collen D; Moreau H; Stockx L; Vanderschueren S
    Circulation; 1996 Jul; 94(2):207-16. PubMed ID: 8674180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety evaluation of recombinant staphylokinase in rhesus monkeys.
    Lu Q; Li Y; Wen L; Guo S; Chen Y; Liu W; Gao Y; Ding L
    Toxicol Pathol; 2003; 31(1):14-21. PubMed ID: 12597445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional significance of NH2- and COOH-terminal regions of staphylokinase in plasminogen activation.
    Gase A; Hartmann M; Gührs KH; Röcker A; Collen D; Behnke D; Schlott B
    Thromb Haemost; 1996 Nov; 76(5):755-60. PubMed ID: 8950786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits.
    Li CJ; Huang J; Yang ZJ; Cao KJ
    Acta Pharmacol Sin; 2007 Jan; 28(1):58-65. PubMed ID: 17184583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
    Vanderschueren S
    Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase.
    Xue X; Li D; Yu J; Ma G; Su Z; Hu T
    Biomacromolecules; 2013 Feb; 14(2):331-41. PubMed ID: 23301655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of staphylokinase with human platelets.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1995 Mar; 73(3):472-7. PubMed ID: 7667831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
    Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
    Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
    Laroche Y; Heymans S; Capaert S; De Cock F; Demarsin E; Collen D
    Blood; 2000 Aug; 96(4):1425-32. PubMed ID: 10942387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY; Johnson RC; Schmahai TJ
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
    Takagi A; Yamashita N; Yoshioka T; Takaishi Y; Sano K; Yamaguchi H; Maeda A; Saito K; Takakura Y; Hashida M
    J Control Release; 2007 Jun; 119(3):271-8. PubMed ID: 17490774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
    Vanderschueren S; Collen D
    Thromb Haemost; 1996 May; 75(5):816-9. PubMed ID: 8725729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics.
    Kronman C; Cohen O; Mazor O; Ordentlich A; Raveh L; Velan B; Shafferman A
    Chem Biol Interact; 2010 Sep; 187(1-3):253-8. PubMed ID: 20005217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final report on the safety assessment of Triethylene Glycol and PEG-4.
    Int J Toxicol; 2006; 25 Suppl 2():121-38. PubMed ID: 17090481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.